Tesamorelin vs Egrifta: what's actually the difference?

Last updated 2026-07-25

Is tesamorelin the same thing as Egrifta?

Yes. Tesamorelin is the generic (nonproprietary) name for the drug. Egrifta is the brand name FDA approved for it, and Egrifta SV is the reformulated version approved later. There isn't a "tesamorelin vs Egrifta" difference the way there's a real difference between, say, two competing molecules. It's one active ingredient, two labels. The confusion comes from the compounding market. Pharmacies operating under 21 U.S.C. 353a can compound tesamorelin from bulk drug substance for individual patients, and that compounded version is chemically the same peptide ^[1][2]. What differs is legal status: Egrifta went through FDA's full approval pathway with phase 3 trial data behind it. Compounded tesamorelin did not go through that pathway for any indication. You can verify Egrifta's approval status directly in Drugs@FDA, FDA's own database of approved drug products. So when people ask "is Egrifta better than tesamorelin," the honest answer is that you're asking whether a specific FDA-approved formulation is different from an unapproved compounded version of the identical molecule. It usually is not different in structure. It is very different in regulatory pedigree.

What is Egrifta actually approved for?

Egrifta (and Egrifta SV) is approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That's it. It is not approved for general fat loss, bodybuilding, anti-aging, or GH deficiency in people without HIV. The approval rests on a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with a safety extension, published in the Journal of Clinical Endocrinology and Metabolism ^[1]. That's the core evidence file regulators reviewed. Everything else, cosmetic use, athletic use, off-label anti-aging use, sits outside that approved indication and outside the trial population that generated the safety data. This matters more than people think. A drug's safety profile is established in a specific population, at a specific dose, for a specific duration. HIV-positive adults with visceral fat accumulation are not the same population as a 45-year-old without HIV looking to lose belly fat. The trial data doesn't automatically transfer.

What does the trial evidence actually show?

The pooled phase 3 analysis found tesamorelin reduced visceral adipose tissue (VAT) in HIV patients with excess abdominal fat, with the drug separating from placebo on CT-measured VAT over 26 weeks, and the safety extension data supporting continued use beyond that window ^[1]. This is the trial set that underlies the Egrifta label. Separate randomized controlled trial data, aggregated in a 2026 meta-analysis of tesamorelin in HIV-associated lipodystrophy, found consistent effects on body composition and hepatic fat, alongside a defined safety profile across the pooled trial population ^[2]. A 2019 multicenter randomized double-blind trial specifically in HIV-associated NAFLD found tesamorelin reduced liver fat content compared to placebo ^[3]. A companion analysis linked visceral fat reduction with improved liver enzyme levels in the same HIV population ^[4]. There's also a fat quality angle that's easy to miss. A 2021 study found tesamorelin improved fat quality (specifically adipose tissue attenuation on imaging) independent of changes in fat quantity, meaning the tissue itself changed character, more than its volume ^[5]. And a 2023 post hoc analysis of the phase 3 placebo-controlled trial looked at outcomes with and without dorsocervical fat pads present at baseline, refining who responds and how ^[6]. All of this evidence is anchored to HIV lipodystrophy patients. None of it is a general population fat-loss trial.

Does tesamorelin work the same way regardless of brand?

Mechanistically, yes. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. It stimulates the pituitary to release the body's own growth hormone, rather than supplying exogenous GH directly ^[7][8]. That mechanism doesn't change based on who manufactured the vial. What can change between manufacturers is peptide purity, degradation product content, and consistency of dose per vial, because compounded products aren't subject to the same pre-market testing and batch release requirements as an FDA-approved drug. Population pharmacokinetic modeling in HIV-infected patients and healthy subjects has characterized how tesamorelin behaves once it's in the body ^[9], but that PK data was generated using the studied drug product, not an arbitrary compounded lot. This is why the dosing and injection details matter regardless of brand. If you're planning to use tesamorelin, understanding how to reconstitute tesamorelin, the best time to take tesamorelin, and correct injection sites affects your results more than which label is on the box.

How does the legal and regulatory status actually differ?

This is the real axis of comparison, not chemistry. Egrifta went through FDA's New Drug Application process: controlled manufacturing, batch testing, a specific approved label, and post-market surveillance obligations. You can look up its approval record in Drugs@FDA. Compounded tesamorelin is produced under a different legal framework entirely. Section 503A of the FD&C Act (21 U.S.C. 353a) allows licensed pharmacies to compound drugs from bulk substances for individual patients under specific conditions, and FDA maintains lists of bulk drug substances eligible for 503A and 503B compounding under 21 CFR 216.23 and 216.24. Being compoundable under these rules is not the same as being FDA-approved for any indication. FDA's own guidance on bulk drug substances used in compounding under section 503A spells out the eligibility criteria and limits. Practically: Egrifta carries an FDA-reviewed label with defined indications, contraindications, and warnings. Compounded tesamorelin carries whatever labeling the compounding pharmacy provides, and none of it constitutes an FDA-reviewed indication claim under 21 CFR 201.128, which defines how "intended use" is established for a drug product.

What are the side effects and safety data for each?

Because Egrifta and compounded tesamorelin share the same active molecule, the known side effect profile from trials applies broadly to tesamorelin itself, not to one brand specifically. Reported effects in trial populations include injection site reactions, joint pain and swelling, muscle aches, and effects on blood glucose given the GH-axis mechanism ^[1][7]. A 2011 study in HIV patients on tesamorelin looked specifically at inflammatory markers and found relationships between visceral fat reduction and changes in inflammatory markers in that population ^[10]. That's a mechanistic safety signal worth knowing, not a general safety guarantee for non-HIV users. What's genuinely different between the two paths is manufacturing oversight, not the drug's biology. An FDA-approved product has consistent batch release testing behind it. A compounded product's consistency depends on the individual pharmacy's quality systems, which FDA does not pre-approve the way it does an NDA product. If you're going the compounded route, sourcing quality and provider oversight matter more, not less, because the safety net of FDA batch review isn't there.

Is compounded tesamorelin cheaper than Egrifta?

Generally, yes, and this is the main reason people ask about alternatives to the branded product at all. Egrifta as a branded, FDA-approved specialty drug carries specialty-pharmaceutical pricing, while compounded tesamorelin from a licensed compounding pharmacy is typically positioned as a lower-cost option. Exact numbers vary by pharmacy, dose, and insurance coverage, so check tesamorelin cost for a fuller breakdown of current pricing ranges rather than relying on a single figure here. Insurance coverage is the other lever. Egrifta, being FDA-approved for a defined medical indication, can be covered by insurance when a patient meets the HIV-lipodystrophy diagnostic criteria on the label. Compounded tesamorelin used off-label for general fat loss typically is not insurance-reimbursable, because it isn't being used for an FDA-recognized indication. So the honest cost comparison isn't just sticker price. It's sticker price for Egrifta if you don't have HIV lipodystrophy (often the full uninsured cost) versus compounded pricing that's lower upfront but comes with no insurance backstop and no FDA quality guarantee.

Who should actually consider Egrifta specifically?

If you have HIV and a clinician has diagnosed HIV-associated lipodystrophy with excess abdominal visceral fat, Egrifta is the on-label, evidence-matched option. It's the product the phase 3 trials were built around, and it's the one your insurance is most likely to recognize ^[1]. Lipodystrophy itself needs a real diagnosis, not a guess based on appearance. Clinical guidance on approaching lipodystrophy syndromes emphasizes a structured diagnostic workup distinguishing generalized from partial forms and identifying the underlying cause ^[11], and a separate methodology paper lays out practical steps for diagnosing lipodystrophy syndromes in clinic ^[12]. If your visceral fat isn't tied to HIV-associated lipodystrophy, you're outside the population Egrifta's trials studied, and that's worth being honest with yourself about before you start.

Who ends up using compounded tesamorelin instead?

In practice, most people asking "tesamorelin vs Egrifta" online don't have HIV-associated lipodystrophy. They're interested in visceral fat reduction or GH-axis support generally, which is off-label use regardless of which product they choose, since neither Egrifta's approval nor the phase 3 trial evidence covers that population ^[1]. This doesn't mean the mechanism is irrelevant outside HIV. GHRH analogues stimulate endogenous GH release, and there's real interest in extrapolating that mechanism to other visceral-fat-reduction contexts ^[7][8]. But extrapolation isn't evidence. Nobody has run an Egrifta-caliber phase 3 trial in HIV-negative adults using visceral fat as the primary endpoint, so anyone using tesamorelin for that purpose is relying on mechanism and off-label reasoning, not a matched evidence base. If you go this route, the sourcing question becomes central, since you're trading FDA-reviewed manufacturing for a compounding pharmacy's own quality standards. That's a real tradeoff, not a technicality.

How does dosing compare between Egrifta and compounded versions?

The Egrifta label specifies a defined subcutaneous dosing regimen established through the phase 3 program, and that's the dose the safety and efficacy data actually apply to ^[1]. Compounded tesamorelin protocols vary by prescriber and pharmacy, and dosing decisions for off-label use aren't backed by the same dose-response data Egrifta's label rests on. Population pharmacokinetic modeling in HIV-infected patients and healthy subjects has characterized how tesamorelin clears the body and how factors like body weight affect exposure ^[9], which is useful background whether you're using the branded or compounded product. But it doesn't replace label-specific dosing guidance. If you're using compounded tesamorelin, get the practical mechanics right: how to reconstitute it correctly, which injection sites rotate best, and what a sensible cycle length looks like. None of that substitutes for the missing phase 3 data in a non-HIV population, but it reduces the chance of avoidable errors.

What about Egrifta SV versus the original Egrifta?

Egrifta SV is a reformulated, lower-volume-injection version of the same tesamorelin molecule, approved after the original Egrifta. The active ingredient and approved indication (HIV-associated lipodystrophy with excess abdominal fat) are the same; the difference is reconstitution and injection volume convenience, not a new efficacy claim. You can confirm current approval status and labeling differences for both directly in Drugs@FDA. This reformulation history is a good reminder that "Egrifta" isn't a fixed single product. It's evolved. What hasn't changed is the underlying evidence base: the phase 3 trials that established efficacy and the defined safety profile remain the reference point for both versions ^[1].

What questions should you ask before choosing either one?

Start with diagnosis: do you actually have HIV-associated lipodystrophy, confirmed through a real clinical workup ^[11][12]? If yes, Egrifta is the evidence-matched, potentially insurance-covered choice. If no, you're in off-label territory no matter which product you pick, and the comparison becomes cost, sourcing quality, and provider oversight rather than efficacy differences. Second, ask about manufacturing oversight. FDA-approved products carry batch testing and NDA-level quality control; compounded products depend on the individual pharmacy's compliance with 503A/503B rules [21 CFR 216.23, 216.24]. Third, ask about total cost including insurance eligibility, more than the per-vial price, since that's where the real cost gap often opens up. Whatever you decide, work with a provider who reviews your case rather than self-directing. Tesamorelin Co's provider-reviewed sourcing guidance points toward pharmacy partners that handle fulfillment under that oversight model, which is the safer default when you're outside Egrifta's on-label population.

Frequently asked questions

Is Egrifta just tesamorelin under a different name?

Yes. Egrifta is the FDA-approved brand name for the drug tesamorelin. There's no separate molecule involved. The difference is regulatory: Egrifta went through FDA's approval process backed by phase 3 trial data ^[1], while other tesamorelin products may be compounded outside that approval pathway.

Can I get Egrifta if I don't have HIV?

Egrifta's FDA approval is specifically for HIV-associated lipodystrophy with excess abdominal fat. A prescriber could technically write it off-label, but the phase 3 evidence and insurance coverage are both built around the HIV lipodystrophy population, so off-label use loses both the evidence match and likely coverage.

Does compounded tesamorelin work as well as Egrifta?

Chemically, compounded tesamorelin is the same molecule, so the mechanism is identical. But it hasn't been through FDA's approval testing, and manufacturing consistency depends on the individual compounding pharmacy rather than NDA-level batch controls, so real-world consistency can vary between pharmacies.

Why is Egrifta so much more expensive than compounded tesamorelin?

Egrifta carries branded, FDA-approved specialty drug pricing and the costs of the approval process behind it, while compounded versions skip that pathway. Insurance can offset Egrifta's cost for diagnosed HIV lipodystrophy patients; compounded tesamorelin used off-label usually isn't covered. See tesamorelin cost for current pricing detail.

What trials support Egrifta's approval?

The core evidence is a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data in HIV patients with excess abdominal fat, published in the Journal of Clinical Endocrinology and Metabolism ^[1]. That dataset underlies the approved label and indication.

Is Egrifta SV different from regular Egrifta?

Egrifta SV is a reformulated version requiring a smaller injection volume, approved after the original Egrifta. The active ingredient and approved indication are unchanged; the reformulation mainly improves injection convenience, not efficacy claims.

Does tesamorelin reduce visceral fat in people without HIV?

There's no phase 3 evidence in a non-HIV population comparable to the trials behind Egrifta's approval. The mechanism (GHRH stimulation of endogenous GH) is the same regardless of HIV status ^[7][8], but using it for general visceral fat loss is off-label and unproven at that evidence level.

What side effects does tesamorelin cause?

Trial data in HIV patients report injection site reactions, joint and muscle discomfort, and effects tied to the GH axis, alongside changes in inflammatory markers linked to visceral fat reduction ^[1][10]. These findings come from the HIV lipodystrophy trial population specifically, not a general population sample.

Is compounded tesamorelin legal?

It can be, under 21 U.S.C. 353a, which permits licensed pharmacies to compound drugs from FDA-recognized bulk substances for individual patients, subject to conditions in 21 CFR 216.23 and 216.24. Legal compounding is not the same as FDA approval of the compounded product for any specific indication.

Does insurance cover tesamorelin?

Insurance is far more likely to cover Egrifta when a patient has a documented HIV-associated lipodystrophy diagnosis matching the FDA-approved indication. Compounded tesamorelin used off-label for general fat reduction is typically not reimbursed, since it falls outside any FDA-recognized indication.

How is tesamorelin dosed differently in Egrifta vs compounded products?

Egrifta's label specifies the dosing regimen used in its phase 3 program, which is what the safety and efficacy data actually reflect ^[1]. Compounded protocols vary by prescriber and aren't backed by the same matched dose-response trial data.

What's the mechanism behind tesamorelin's fat effects?

Tesamorelin is a GHRH analogue that stimulates the pituitary to release the body's own growth hormone, rather than delivering GH directly ^[7][8]. In HIV lipodystrophy trials, this led to measurable visceral fat and, separately, liver fat reductions ^[3][4].

Sources

1. Journal of Clinical Endocrinology and Metabolism, 2010 (PMID 20554713): Pooled analysis of two phase 3 double-blind placebo-controlled trials with safety extension data underlies tesamorelin's approval for HIV-associated lipodystrophy with excess abdominal fat
2. Obesity Research & Clinical Practice, 2026 (PMID 41545261): Meta-analysis of randomized controlled trials found consistent effects on body composition, hepatic fat, and defined safety outcomes for tesamorelin in HIV-associated lipodystrophy
3. The Lancet HIV, 2019 (PMID 31611038): Randomized double-blind multicenter trial found tesamorelin reduced liver fat content in HIV-associated NAFLD compared to placebo
4. AIDS, 2017 (PMID 28832410): Visceral fat reduction with tesamorelin was associated with improved liver enzyme levels in HIV patients
5. AIDS, 2021 (PMID 33756511): Tesamorelin improved fat quality (tissue attenuation) independent of changes in fat quantity
6. Journal of Clinical and Translational Science, 2023 (PMID 36845310): Post hoc analysis of phase 3 trial examined tesamorelin effects with and without dorsocervical fat present at baseline
7. Nature Reviews Drug Discovery, 2011 (PMID 21283099): Tesamorelin is a growth hormone-releasing hormone analogue that stimulates pituitary GH release
8. Expert Opinion on Investigational Drugs, 2009 (PMID 19243281): Tesamorelin functions as a human growth hormone releasing factor analogue
9. Clinical Pharmacokinetics, 2015 (PMID 25358450): Population pharmacokinetic analysis characterized tesamorelin exposure in HIV-infected patients and healthy subjects
10. AIDS, 2011 (PMID 21516030): Tesamorelin's effect on inflammatory markers in HIV patients was related to visceral adipose tissue reduction
11. Journal of Clinical Endocrinology and Metabolism, 2022 (PMID 35137140): Clinical approach to lipodystrophy requires structured diagnostic workup distinguishing generalized from partial forms
12. Annales d'Endocrinologie, 2012 (PMID 22748602): Diagnosing lipodystrophy syndrome requires specific clinical and laboratory workup steps
13. 21 U.S.C. 353a, pharmacy compounding: Section 503A permits licensed pharmacies to compound drugs from bulk substances for individual patients under specified conditions
14. 21 CFR 216.23, the 503A Bulks List: Federal regulation defines which bulk drug substances are eligible for compounding under section 503A
15. Drugs@FDA, FDA-approved drug products database: Egrifta and Egrifta SV approval status and labeling can be verified directly through FDA's approved drug products database